Quarterly Journal Volume 54, Issue 1
In This Section
The Quarterly Journal is dedicated to presenting materials relating to intellectual property matters and is published four times per year. Editorial Board members (all of whom are lawyers) are selected based upon demonstrated interest and experience, and student staff members are selected from the students of the GWU Law School.
QJ 54.1 - Mending the Fence: Commercial Success & the Blocking Patent Defense in Pharmaceutical Litigation
John Jarosz, Andrea Hugill, Anna Gumen, and Michael Chapman
MENDING THE FENCE: COMMERCIAL SUCCESS & THE BLOCKING PATENT DEFENSE IN PHARMACEUTICAL LITIGATION
Commercial success often is a crucial after-the-fact consideration in litigations assessing whether a patent was nonobvious or not. Its evaluation usually entails assessing whether a patented invention (often, product) has achieved success in the marketplace and whether that success is due to the patented features. In pharmaceutical litigation, the blocking patent defense increasingly has been invoked to counter a patent owner's reliance on a showing of commercial success. The core blocking patent argument is that the success of the patented invention stems not from the at-issue patent being considered for obviousness, but instead from the preclusive effect of an earlier, pre-existing "blocking" patent that prevented third parties from pursuing inventions that led to the at-issue patent. The blocking patent defense appears to be increasingly invoked, and much of the time, has succeeded. Despite its growing use and acceptance, the foundations (or footers) of the blocking patent defense are less solid than they may seem. While commercial success is valuable in a nonobviousness analysis because it is intended to be rooted in real-world evidence, courts often discount this evidence in the context of a blocking patent defense and instead base their conclusions solely on an expert's opinion that blocking may have occurred. This approach risks undervaluing certain patented inventions by relying on speculative assertions that a blocking patent deterred others, even when real world evidence suggests otherwise-namely, that the blocking patent did not block competitive R&D, and that the patented invention succeeded because it was genuinely innovative and nonobvious.
QJ 54.1 - Secret Methods, Public Sales: Reimagining the On-Sale Bar for Process Patents
Sameer Agrawal
The on-sale bar, under 35 U.S.C. §102(a)(1), does not allow an inventor to obtain a patent if they sell their invention more than one year before they file a patent application. This Note explores the Federal Circuit's interpretation in Celanese v. Int’l. Corp. v. ITC , which held that sales of products made using secret processes trigger the on-sale bar, invalidating later process patent claims. The analysis argues that Celanese's interpretation contradicts the America Invents Act's plain language, which requires the "claimed invention" itself to be on sale and "available to the public." The Note considers how the Supreme Court's Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc. decision, which Celanese relies upon, addressed a narrower question and does not support Celanese's broader interpretation. The Note then proposes a specific legislative solution through an amendment to § 102(a)(1) that would create a carveout for method claims when product sales don't disclose the underlying process, thereby promoting international harmonization of international patent standards and creating a more level playing field for small companies that face barriers under the current interpretation.
QJ 54.1 - The Limits of Territoriality: Addressing Unauthorized Use of Foreign Famous Marks in the United States
Layla Huang
QJ 54.1 - Hidden in Plain Sight: Moral Rights, Cultural Stewardship, & “Destruction” After Kerson
Hannah Kressel-Levinson
This Note uses the Second Circuit’s 2023 decision in Kerson v. Vermont Law School, 79 F.4th 257, as a jumping off point to consider the scope and purpose of the moral rights provision of the United States Copyright Act, the Visual Artists Rights Act (“VARA”). Specifically, this Note addresses VARA’s contours in the context of the responsibility cultural institutions have to the public to preserve, and occasionally wrestle with, creative works. Furthermore, this Note analyzes the Second Circuit’s analysis of “destruction” in Kerson, proposing future modes of analysis that better address the full breadth of an artist’s work.
Upcoming Events
-
2026 Patent Prosecution Bootcamp - Arlington, VA
March 4 to 6, 2026 | Up to 1235 minutes, including 60 Ethics minutes
-
AIPLA CLE Webinar: Damages 2025 Year-in-Review: Lessons and Litigation Strategies
March 11, 2026 2:00 PM to 3:30 PM | Eligible for up to 90 Mins CLE
-
AIPLA LinkedIn Live: What the 2025 AIPLA Economic Survey Reveals About IP Practice Today
March 12, 2026 12:00 PM to 12:45 PM
-
2026 Women in IP Global Networking Event
April 16, 2026
The annual Global Networking Event connects intellectual property practitioners from around the world for a day of networking, education, and creating meaningful connections. This year’s theme, Rooted in Real - Women in IP Redefining the Narrative, is an opportunity for the AIPLA Women in IP Law Committee to celebrate authentic experiences, foster genuine connections, and showcase the real stories of women shaping the field of intellectual property law. -
Careers in IP
April 22, 2026 12:30 PM to 1:30 PM | No CLE

